NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

计划入组 320 人 · 首次发布于 2026 年 7 月 6 日

Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers

计划入组 8 人 · 首次发布于 2026 年 6 月 29 日

Agomab's Ontunisertib Achieves Primary Safety Endpoint in First-in-Class Phase 2a Trial for Fibrostenosing Crohn's Disease

Agomab Unveils Design for First-Ever Phase 2b Trial in Fibrostenosing Crohn's Disease with Oral ALK5 Inhibitor Ontunisertib

Agomab and SpyGlass Raise Combined $350M in Biotech IPOs, Signaling Market Recovery